Matching articles for "Betaseron"
Issue 1722 · February 17, 2025 Free
In Brief: Anaphylaxis with Glatiramer Acetate

The FDA has required a new boxed warning in the label of the subcutaneously injected immunomodulatory drug glatiramer acetate ( Copaxone , Glatopa , and generics) about a risk of anaphylaxis. Glatiramer has…

Med Lett Drugs Ther. 2025 Feb 17; 67(1722):32 doi:10.58347/tml.2025.1722e
The FDA has required a new boxed warning in the label of the subcutaneously injected immunomodulatory drug glatiramer acetate ( Copaxone , Glatopa , and generics) about a risk of anaphylaxis. Glatiramer has been used for years to treat relapsing forms of multiple sclerosis (MS).
Issue 1620 · March 22, 2021
Drugs for Multiple Sclerosis

Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations,…

Med Lett Drugs Ther. 2021 Mar 22; 63(1620):42-8
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Issue 1523 · June 19, 2017
Ocrelizumab (Ocrevus) for MS

The FDA has approved ocrelizumab ( Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first…

Med Lett Drugs Ther. 2017 Jun 19; 59(1523):98-101
The FDA has approved ocrelizumab ( Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first anti-CD20 monoclonal antibody to be approved for treatment of MS and the first disease-modifying drug to be approved in the US for primary progressive MS.
Issue 1496 · June 6, 2016
Drugs for Multiple Sclerosis

Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):71-4
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as fatigue, depression, and pain, and corticosteroids for acute exacerbations.
Issue 1468 · May 11, 2015
Peginterferon Beta-1a (Plegridy) for Multiple Sclerosis

The FDA has approved a pegylated form of interferon beta-1a ( Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).

Med Lett Drugs Ther. 2015 May 11; 57(1468):67-9
The FDA has approved a pegylated form of interferon beta-1a ( Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).
Issue 1418 · June 10, 2013
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis

The FDA has approved dimethyl fumarate ( Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years…

Med Lett Drugs Ther. 2013 Jun 10; 55(1418):45-7
The FDA has approved dimethyl fumarate ( Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years for this indication.
Issue 1350 · November 1, 2010
Interferon Beta-1b (Extavia) for Multiple Sclerosis

The FDA has approved a new interferon beta-1b product ( Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron (Bayer); both are produced in the…

Med Lett Drugs Ther. 2010 Nov 1; 52(1350):86-7
The FDA has approved a new interferon beta-1b product ( Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron (Bayer); both are produced in the same factory and packaged separately.
Issue 1307 · March 9, 2009
Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis

Alemtuzumab (Campath) , a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ…

Med Lett Drugs Ther. 2009 Mar 9; 51(1307):17-8
Alemtuzumab (Campath) , a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS).
Issue 1202 · February 14, 2005
Natalizumab (Tysabri) for Relapsing Multiple Sclerosis

Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and…

Med Lett Drugs Ther. 2005 Feb 14; 47(1202):13-5
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for treatment of MS; they generally reduce the number of relapses by about 30% compared to placebo, and have been shown to be safe and effective for periods ranging from 4 to 10 years.
Issue 1141 · October 14, 2002
Beta Interferons for Multiple Sclerosis

Three beta interferons are widely used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

Med Lett Drugs Ther. 2002 Oct 14; 44(1141):88-9
Three beta interferons are widely used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
Issue 1004 · July 4, 1997
Glatiramer Acetate for Relapsing Multiple Sclerosis

Glatiramer acetate ( Copaxone - Teva Marion Partners), formerly known as copolymer-l, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis…

Med Lett Drugs Ther. 1997 Jul 4; 39(1004):61-2
Glatiramer acetate ( Copaxone - Teva Marion Partners), formerly known as copolymer-l, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (MS). Interferon β-1b ( Betaseron ) and interferon β-1a ( Avonex - Medical Letter, 38:63, 1996) were previously approved for this indication.
Issue 979 · July 19, 1996
Interferon Beta-1a for Relapsing Multiple Sclerosis

Interferon β-1a ( Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS).…

Med Lett Drugs Ther. 1996 Jul 19; 38(979):63-4
Interferon β-1a ( Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS). Interferon β-1a ( Betaseron - Berlex), a recombinant analog of interferon β that differs from interferon β-1a in having a serine substituted for a cysteine and in not being glycosylated, was previously approved for this indication (Medical Letter, 35:61, 1993; BW van Oosten et al, Drugs, 49:200, 1995).
Issue 900 · July 9, 1993
Interferon Beta-1b for Multiple Sclerosis

Interferon β-1b ( Betaseron - Berlex), an analog of human interferon β pro-duced in E. coli, may soon be approved by the US Food and Drug Administration for treatment of relapsing-remitting multiple…

Med Lett Drugs Ther. 1993 Jul 9; 35(900):61-2
Interferon β-1b ( Betaseron - Berlex), an analog of human interferon β pro-duced in E. coli, may soon be approved by the US Food and Drug Administration for treatment of relapsing-remitting multiple sclerosis (MS), the most common form of the disease (G Mitchell, Med Clin North Am, 77:231, 1993).